JP2023535444A5 - - Google Patents

Info

Publication number
JP2023535444A5
JP2023535444A5 JP2023504622A JP2023504622A JP2023535444A5 JP 2023535444 A5 JP2023535444 A5 JP 2023535444A5 JP 2023504622 A JP2023504622 A JP 2023504622A JP 2023504622 A JP2023504622 A JP 2023504622A JP 2023535444 A5 JP2023535444 A5 JP 2023535444A5
Authority
JP
Japan
Prior art keywords
complex according
antibody
oligonucleotide
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023504622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535444A (ja
JP7851294B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/040987 external-priority patent/WO2022020106A1/en
Publication of JP2023535444A publication Critical patent/JP2023535444A/ja
Publication of JP2023535444A5 publication Critical patent/JP2023535444A5/ja
Application granted granted Critical
Publication of JP7851294B2 publication Critical patent/JP7851294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023504622A 2020-07-23 2021-07-09 顔面肩甲上腕型筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 Active JP7851294B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063055768P 2020-07-23 2020-07-23
US63/055,768 2020-07-23
US202063061839P 2020-08-06 2020-08-06
US63/061,839 2020-08-06
US202163143828P 2021-01-30 2021-01-30
US63/143,828 2021-01-30
US202163181456P 2021-04-29 2021-04-29
US63/181,456 2021-04-29
PCT/US2021/040987 WO2022020106A1 (en) 2020-07-23 2021-07-09 Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026066450A Division JP2026129755A (ja) 2020-07-23 2026-04-14 顔面肩甲上腕型筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2023535444A JP2023535444A (ja) 2023-08-17
JP2023535444A5 true JP2023535444A5 (cg-RX-API-DMAC7.html) 2024-07-11
JP7851294B2 JP7851294B2 (ja) 2026-04-24

Family

ID=79729849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504622A Active JP7851294B2 (ja) 2020-07-23 2021-07-09 顔面肩甲上腕型筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用

Country Status (11)

Country Link
US (1) US20230272065A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185314A4 (cg-RX-API-DMAC7.html)
JP (1) JP7851294B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230046297A (cg-RX-API-DMAC7.html)
CN (1) CN116348139A (cg-RX-API-DMAC7.html)
AU (1) AU2021313057A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001003A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186746A1 (cg-RX-API-DMAC7.html)
IL (1) IL299666A (cg-RX-API-DMAC7.html)
MX (1) MX2023000961A (cg-RX-API-DMAC7.html)
WO (1) WO2022020106A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
CN116096890A (zh) 2020-04-02 2023-05-09 米雷楚莱股份有限公司 使用工程化寡核苷酸的靶向抑制
AU2021313058A1 (en) * 2020-07-23 2023-03-30 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
EP4185320A4 (en) * 2020-07-23 2025-10-08 Dyne Therapeutics Inc MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023283623A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
WO2024011135A2 (en) * 2022-07-06 2024-01-11 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
AU2023303022A1 (en) * 2022-07-06 2025-01-02 Dyne Therapeutics, Inc. Cns targeting complexes and uses thereof
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
WO2025255283A1 (en) * 2024-06-07 2025-12-11 Dyne Therapeutics, Inc. Dosing of muscle targeting complexes for treating facioscapulohumeral muscular dystrophy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10538763B2 (en) * 2015-01-16 2020-01-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of DUX4
CA2990785C (en) * 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
GB201512365D0 (en) * 2015-07-15 2015-08-19 King S College London Novel therapy
FR3049951A1 (fr) * 2016-04-12 2017-10-13 Univ Rabelais Francois Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
DK3473270T5 (da) 2016-06-20 2024-09-09 Genahead Bio Inc Konjugat af antistof-lægemiddel
KR20240172236A (ko) * 2017-01-06 2024-12-09 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
UY38247A (es) * 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3829594A4 (en) * 2018-08-02 2022-05-11 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
EP3830259A4 (en) * 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
CN112955154A (zh) * 2018-08-02 2021-06-11 达因疗法公司 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途
CN112930193A (zh) * 2018-08-02 2021-06-08 达因疗法公司 肌肉靶向复合物及其在治疗肌肉萎缩中的用途
IL312067B2 (en) * 2018-12-21 2025-08-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2021532832A5 (cg-RX-API-DMAC7.html)
JP2021533200A5 (cg-RX-API-DMAC7.html)
JP2021533197A5 (cg-RX-API-DMAC7.html)
JP2024546436A5 (cg-RX-API-DMAC7.html)
JP2024525614A5 (cg-RX-API-DMAC7.html)
JP2023535078A5 (cg-RX-API-DMAC7.html)
JP2024501872A5 (cg-RX-API-DMAC7.html)
JP2021533199A5 (cg-RX-API-DMAC7.html)
JP2023512442A5 (cg-RX-API-DMAC7.html)
JP2023535074A5 (cg-RX-API-DMAC7.html)
US9163241B2 (en) Cell-type specific aptamer-siRNA delivery system for HIV-1 therapy
JP2023510351A5 (cg-RX-API-DMAC7.html)
KR101605932B1 (ko) Hsf1-관련 질환을 치료하기 위한 유기 조성물
Wullner et al. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2
KR20230044242A (ko) 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
EP2121929B1 (en) Targeted delivery of sirna
JP2023512441A5 (cg-RX-API-DMAC7.html)
JP2008527993A (ja) 特異性及び送達の改善のためのsiRNA分子、shRNA分子又はアンチセンス分子及び機能的実体を含む複合体
IL317871A (en) Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy
CA3209418A1 (en) Compositions and methods for modulating pnpla3 expression
CA3124664A1 (en) Compositions and methods for inhibiting hmgb1 expression
US20250290071A1 (en) Stat3 targeting oligonucleotides and uses thereof
US20250205352A1 (en) COMPOSITIONS AND METHODS FOR MODULATING NaV1.8
AU2019213316B2 (en) Organic compositions to treat HSF1-related diseases
Prater Antisense oligonucleotides directed to the HIV-1 Rev Response Element: Effects of nucleotide modification on oligo binding affinity, nuclease stability, and cellular uptake